Regeneron Pharmaceuticals customer service interviews test whether candidates understand how patient support and HUB services work for specialty biologic medicines – where the complexity of biologic therapy access involves prior authorization coordination, cold chain supply chain management, pharmacovigilance adverse event intake, and patient financial assistance programs that are unlike the customer service functions of consumer or standard pharmaceutical companies. Customer service at Regeneron spans HUB services and patient access support (where Regeneron's HUB services function as the central coordination point between prescribing physicians, specialty pharmacies, and patients who are starting DUPIXENT or other biologic therapies – verifying insurance benefits, initiating and tracking prior authorization submissions, providing physician offices with PA status updates, coordinating with specialty pharmacy for prescription dispensing, and enrolling patients who face coverage gaps or high cost-sharing into Regeneron Cares assistance programs), adverse event intake and pharmacovigilance reporting (where patients, caregivers, and healthcare providers who contact Regeneron with reports of adverse events experienced with DUPIXENT, EYLEA, or LIBTAYO create intake obligations under FDA regulations that require Regeneron to collect case information, evaluate causality, and report serious and unexpected adverse events within prescribed timelines – and where customer service staff who take these calls must be trained to collect the minimum required pharmacovigilance data elements even when callers do not understand why specific medical information is requested), specialty pharmacy coordination for cold chain biologics (where DUPIXENT requires storage at 2-8 degrees Celsius and must be dispensed from specialty pharmacies with cold chain capability, cold chain exceptions during shipping or home storage create patient counseling and product replacement considerations that customer service manages in coordination with specialty pharmacy and quality teams), and nurse educator programs (where Regeneron deploys nurse educators who provide injection training to patients starting DUPIXENT self-injection, answer clinical questions about managing their disease during biologic therapy, and improve patient confidence in self-administration that predicts adherence over the full treatment course). Interviewers evaluate whether candidates understand HUB services coordination for biologic access, pharmacovigilance adverse event intake obligations, cold chain management for temperature-sensitive biologics, and patient education programs that support biologic therapy adherence.
Start your free Regeneron Pharmaceuticals Customer Service practice session.
What interviewers actually evaluate
HUB Services Coordination, Pharmacovigilance Reporting, and Patient Support for Specialty Biologics
Regeneron customer service interviews probe whether candidates understand how patient support for specialty biologics differs from customer service for consumer products or standard pharmaceutical therapies in the access coordination complexity (a patient whose physician has prescribed DUPIXENT does not simply pick it up at a retail pharmacy – the prescription routes to a specialty pharmacy through the HUB, benefits investigation confirms what coverage the patient's insurance plan provides, PA submission must be completed and approved before dispensing can occur, and if PA is denied, appeal preparation and submission must happen quickly enough that the patient's initiation of therapy is not delayed by weeks of administrative process, requiring HUB services staff who understand both the clinical criteria that underpin PA approvals and the administrative mechanics of the payers they encounter most frequently), the pharmacovigilance legal obligation (customer service staff who receive adverse event reports from patients or healthcare providers are acting as the initial data collection point for Regeneron's pharmacovigilance system – their obligation to collect minimum case information including patient identifier, reporter contact information, product name, and adverse event description is not a customer service best practice but a regulatory requirement under FDA regulations and Regeneron's pharmacovigilance agreements with Sanofi for co-promoted products, and their failure to collect required information or to route reports to the pharmacovigilance team within required timeframes creates regulatory compliance exposure), and the patient adherence impact of service quality (biologic therapy is most effective when patients inject consistently according to schedule – DUPIXENT's clinical benefit depends on continuous IL-4/IL-13 blockade, and patients who miss injections because they run out of product, cannot navigate refill processes, or experience adverse events they are unsure how to manage are less likely to achieve the disease control that predicts long-term adherence, meaning that customer service quality directly affects clinical outcomes in a way that is not true for customer service in most industries).
The co-promotion complexity with Sanofi creates a customer service coordination dimension that requires attention: adverse events reported for DUPIXENT and LIBTAYO involve co-promoted products where both Regeneron and Sanofi have pharmacovigilance reporting obligations, and cases reported to either company must be shared with the partner within defined exchange timelines to ensure that both companies' global safety databases reflect the same adverse event profile for these shared products.
What gets scored in every session
Specific, sentence-level feedback.
| Dimension | What it measures | How to answer |
|---|---|---|
| HUB services and prior authorization coordination | Do you understand how HUB services manage the prior authorization process for biologic specialty medicines – what benefits verification involves, how PA submissions are prepared and submitted to payers, what appeal processes are available when PAs are denied, and how to coordinate specialty pharmacy dispensing after PA approval? We flag customer service answers that describe PA support as administrative form completion rather than access strategy for high-cost biologic medicines. | Benefits investigation methodology, PA submission and tracking, appeal preparation for denied PAs |
| Pharmacovigilance adverse event intake | Can you describe the regulatory requirements for collecting adverse event reports received by customer service staff – what minimum case information must be collected, what timeframe requirements apply to serious adverse event reporting, and how to handle a call from a patient who reports a medical event but does not want to provide identifying information that FDA regulations require for a complete report? We score whether your pharmacovigilance approach demonstrates understanding of regulatory collection requirements rather than treating adverse event calls as general complaint handling. | Minimum case data element collection, serious AE reporting timeframes, incomplete report management |
| Cold chain management for temperature-sensitive biologics | Do you understand the cold chain requirements for biologics like DUPIXENT – what temperature conditions must be maintained from specialty pharmacy dispensing through patient home storage and administration, how to advise patients who report temperature excursions, and when a product that experienced temperature excursion should be replaced rather than used? We detect customer service answers that treat biologic storage requirements as generic medication handling advice. | Temperature excursion assessment, patient storage counseling, product replacement decision criteria |
| Patient adherence support and nurse educator programs | Can you describe how nurse educator programs support biologic therapy adherence – what types of patient questions and concerns nurse educators address, how injection training improves self-administration confidence, and how to identify patients at risk for early discontinuation based on early therapy experience signals? We flag customer service answers that treat patient education as one-time onboarding rather than ongoing adherence support. | Injection training effectiveness, early discontinuation risk identification, ongoing adherence intervention |
How a session works
Step 1: Choose a Regeneron Pharmaceuticals customer service scenario – HUB services prior authorization coordination for DUPIXENT patient access, pharmacovigilance adverse event intake and reporting compliance, cold chain management for temperature-sensitive biologic products, or nurse educator program design for biologic therapy initiation and adherence.
Step 2: The AI interviewer asks realistic Regeneron-style questions: how you would manage the situation where a patient whose DUPIXENT PA was approved in December receives a new PA denial in January because their insurance plan changed at year-end and the new plan has different step therapy requirements that were not met under the prior plan – including what the HUB services team should do immediately to preserve the patient's therapy continuation while the new PA process proceeds, how you would train new customer service representatives to handle calls where patients report potential adverse events – specifically focusing on what information to collect, how to handle patients who refuse to provide contact information, and what constitutes a serious adverse event that requires expedited routing to the pharmacovigilance team, or how you would respond to a patient who calls to report that her DUPIXENT prefilled syringes were left in a non-refrigerated package on her doorstep during summer delivery and are now at room temperature after what she estimates was 3 hours of uncontrolled storage.
Step 3: You respond as you would in the actual interview. The system scores your answer on HUB services PA coordination, pharmacovigilance intake obligations, cold chain management, and patient adherence support.
Step 4: You get sentence-level feedback on what demonstrated genuine specialty biologic customer service expertise and what needs stronger pharmacovigilance regulation knowledge or HUB services process specificity.
Frequently Asked Questions
How does the HUB services model support biologic patient access?
Regeneron's HUB services act as the centralized patient support infrastructure that coordinates the multiple parties and processes required for a specialty biologic prescription to result in a patient receiving their medication. After a physician electronically enrolls a patient in the HUB or a prescription is submitted, the HUB team conducts benefits investigation to determine what the patient's insurance covers for the prescribed biologic, whether prior authorization is required, what the patient's out-of-pocket cost exposure will be after insurance, and which specialty pharmacy within the patient's network can dispense the product. For patients who require PA, the HUB prepares and submits the PA request with clinical documentation from the prescriber's office, tracks approval or denial, and initiates appeal processes when PAs are denied on clinical or administrative grounds. For patients with high out-of-pocket cost despite insurance coverage, the HUB coordinates enrollment in Regeneron Cares patient assistance or the co-pay card program that reduces patient cost-sharing.
What are the FDA pharmacovigilance requirements for adverse event collection?
FDA regulations require pharmaceutical manufacturers to collect and report adverse events associated with their marketed products – serious adverse events must be reported to FDA within 15 calendar days of the manufacturer's receipt of the case if the event is unexpected or not previously described in the product labeling, and all adverse events must be captured in the manufacturer's safety database. Customer service staff who receive calls reporting medical events must be trained to collect the four minimum case elements required for a valid adverse event report: an identifiable patient, an identifiable reporter, the product name or description, and an adverse event description. Callers who are reluctant to provide identifying information should be encouraged to provide it with explanation of why it is needed, but even incomplete cases with only partial information must be entered into the safety database and routed to the pharmacovigilance team. The pharmacovigilance team assesses completed cases for regulatory reportability and submits MedWatch forms to FDA within the applicable reporting timeline.
What are the cold chain requirements for DUPIXENT storage?
DUPIXENT (dupilumab) prefilled syringes must be stored in a refrigerator at 2 to 8 degrees Celsius – standard refrigerator temperature. Patients who self-inject can allow a syringe to warm to room temperature below 25 degrees Celsius for up to 14 days before injection, which improves injection comfort. Syringes that have been at room temperature for more than 14 days should not be returned to the refrigerator and should not be used – the 14-day window is the defined stability period for room temperature storage. Temperature excursions during shipping or home storage – where the product was exposed to temperatures outside the 2-8 degree refrigerated range or above 25 degrees Celsius during room temperature storage – require assessment based on the duration and degree of the excursion. Patients who report temperature excursions should be counseled not to use the affected product and to contact their specialty pharmacy for replacement, and customer service should document the excursion for quality and safety assessment.
How do nurse educators support biologic therapy initiation?
Regeneron's nurse educators – typically registered nurses or other clinical professionals employed by Regeneron – contact patients who are starting DUPIXENT self-injection to provide injection training and answer clinical questions about their therapy. Many patients initiating biologic self-injection have never given themselves an injection and have anxiety about the process, technique, and managing injection site reactions. Nurse educators conduct telephone or in-person training on syringe preparation, injection site selection and rotation, injection technique, and needle disposal, and they follow up with patients after the first few injections to address problems and reinforce confidence. Beyond injection technique, nurse educators can answer questions about expected timeline for clinical response – patients with atopic dermatitis may not see full skin clearing for 12-16 weeks, and patients who expect faster response may discontinue prematurely without the reassurance that their clinical trajectory is normal – which is one of the most impactful adherence interventions a nurse educator makes.
How does Regeneron Cares support patients with access challenges?
Regeneron Cares is Regeneron's patient assistance program that provides financial support for eligible patients who are uninsured or underinsured and cannot afford their Regeneron medications. For uninsured patients who meet income eligibility criteria, Regeneron Cares can provide DUPIXENT or other products at no cost. For commercially insured patients with significant out-of-pocket exposure despite coverage, co-pay assistance cards reduce patient out-of-pocket costs to defined maximum amounts per year, eliminating the cost burden that can cause patients to delay starting therapy or to discontinue after starting. For Medicare beneficiaries who are not eligible for commercial co-pay assistance (CMS prohibits co-pay card use for Medicare beneficiaries in most circumstances), Regeneron offers separate assistance programs that navigate the Medicare Part D cost-sharing structure. HUB services staff who identify patients with potential access challenges route them to Regeneron Cares enrollment, and patient services staff process applications and provide real-time eligibility determinations.
Also practice
One full session free. No account required. Real, specific feedback.
